INKT Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
MiNK Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.72 |
| 52 Week High | US$1.90 |
| 52 Week Low | US$0.57 |
| Beta | 0.048 |
| 11 Month Change | -3.86% |
| 3 Month Change | -8.85% |
| 1 Year Change | -29.40% |
| 33 Year Change | -93.83% |
| 5 Year Change | n/a |
| Change since IPO | -94.00% |
Recent News & Updates
Recent updates
MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely
Oct 26
Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?
Jun 28Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?
Mar 18MiNK Therapeutics GAAP EPS of -$0.18
Aug 16MiNK Therapeutics GAAP EPS of -$0.18
Aug 09MiNK Therapeutics A Bargain For Potential Cell Therapies
Jun 23We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely
May 05Shareholder Returns
| INKT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.2% | 4.0% | 2.0% |
| 1Y | -29.4% | 18.0% | 32.4% |
Return vs Industry: INKT underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: INKT underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| INKT volatility | |
|---|---|
| INKT Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INKT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INKT's weekly volatility has decreased from 11% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 31 | Jen Buell | minktherapeutics.com |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors.
MiNK Therapeutics, Inc. Fundamentals Summary
| INKT fundamental statistics | |
|---|---|
| Market cap | US$28.63m |
| Earnings (TTM) | -US$13.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.1x
P/E RatioIs INKT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INKT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.78m |
| Earnings | -US$13.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -26.6% |
How did INKT perform over the long term?
See historical performance and comparison